Diagnostic Technology

ABS-103R
ABS-205
Alzheimer's Disease
Parkinson's Disease
Stroke

ABS-103R: THE NEXT GENERATION VALPROATE

ABS-103R is a potent single isomer analogue of a commonly prescribed anti-convulsant agent known as valproate. Valproate is a frontline treatment for epilepsy and is also indicated for migraine prophylaxis (prevention) and treatment of mania associated with bipolar depression. Sales of valproate are approximately $1 billion worldwide. Despite its widespread use valproate has serious side effects, which include teratogenicity (birth defects and neurological damage), sedation and fatal hepatotoxicity (liver damage). ABS, in collaboration with researchers in its Global Scientific Network®, has managed to isolate the characteristics of valproate that account for its efficacy and those characteristics that cause serious side effects. ABS-103R has been shown to be free of the serious side effects associated with valproate particularly birth defects and sedation. ABS-103R is intended for the treatment and prevention of epilepsy, migraine headache and mania associated with bipolar depression.

Evaluation of ABS-103R: A Comparison with Valproate
Drug
Anti-convulsant Action (%)
Sedation (%)
Embryo Lethality (%)
Embryo Neural Defects (%)
Valproate
100
33
49
42
ABS-103R
100
0
9
0
Control
0
9
0
• ABS-103R demonstrates an improved safety profile compared with Valproate.

ABS-103R Demonstrates a Longer Duration of Action Compared to Valproate

• ABS-103 demonstrates a significantly longer duration of action in the cortical ramp model of epilepsy compared to valproate. A longer duration of action is important as it represents a sustained therapeutic effect, which can result in less frequent drug administration.
More